Table 3.
Trial medication during induction therapy, high-dose melphalan and lenalidomide maintenance therapy.
| Medication mean (interquartile ranges) | S1 | S2 | S3 | p |
|---|---|---|---|---|
| Induction therapy | ||||
| Bortezomib (cumulative mg/m2) | 15.1 (14.7–15.7) | 15.0 (15.1–15.7) | 14.8 (14.5–15.7) | 0.56 |
| Doxorubicine (cumulative mg/m2) | 106.4 (105.7–109.0) | 107.5 (106.7–109.6) | 105.9 (104.9–108.7) | 0.13 |
| Cyclophosphamide (cumulative mg/m2) | 2564.2 (2619.6–2704.9) | 2600.8 (2608.7–2700.0) | 2574.8 (2647.3–2702.3) | 0.52 |
| Dexamethasone (mg/cycle) | 277.4 (240–320) | 285.2 (240–320) | 270.5 (240–320) | <0.001 |
| MEL200/ASCT | ||||
| First ASCT (melphalan, mg/m2/cycle) | 196.4 (200.0–200.0) | 197.8 (200.0–200.0) | 206.3 (200.0–200.0) | 0.05 |
| Second ASCT (melphalan, mg/m2/cycle) | 195.9 (200.0–200.0) | 195.5 (200.0–200.0) | 178.0 (183.0–200.0) | <0.001 |
| Maintenance therapy | ||||
| Lenalidomide (mg/day) | 11.5 (10.0–15.0) | 10.6 (10.0–15.0) | 10.6 (10.0–15.0) | <0.001 |
Applied doses of trial medication with respect to the three age groups ≤60 years (S1), 61–65 years (S2) and 66–70 years (S3).
Bold p values are statistically significant.
MEL200 melphalan 200 mg/m2; ASCT autologous blood stem cell transplantation.